The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia

Gynecologic and Obstetric Investigation

Volumn 69, Issue 1, 2010, Pages 1-13

  Böger, Rainer H ^a   Diemert, Anke ^a   Schwedhelm, Edzard ^a   Lüneburg, Nicole ^a   Maas, Renke ^a   Hecher, Kurt ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Preeclampsia; Symmetric dimethylarginine

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE; DIMETHYLARGININASE; DIMETHYLARGININASE INHIBITOR; ENZYME INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MATERNAL HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE ARTERY; UTERUS BLOOD FLOW; VASCULAR ENDOTHELIUM;

ARGININE; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; NITRIC OXIDE SYNTHASE; PRE-ECLAMPSIA; PREGNANCY;

EID: 70349894134     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245940     Document Type: Review

References (99)

1. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365: 785-799.
2. Lain KY, Roberts JM: Contemporary concepts of the pathogenesis and management of preeclampsia. J Am Med Assoc 2002; 287: 3183-3186.
3. Wallis AB, Saftlas AF, Hsia J, Atrash HK: Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21: 521-526.
4. AHC Consilium.at Hypertonie in der Schwangerschaft. http://www.akh- consilium. at/daten/schwangerschaftshypertonie. htm (accessed March 27, 2006).
5. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, Goldenberg RL, Joffe G: Risk factors associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol 1997; 177: 1003-1010. (Pubitemid 27525346)
6. Tsukimori K, Ishida K, Maeda H, Koyanagi T, Nakano H: The placenta as a possible source of the factor causing endothelial cell injury in preeclampsia. Hypertens Pregnancy 1994; 13: 358.
7. Cross JC: Trophoblast function in normal and preeclamptic pregnancy. Fetal Matern Med Rev 1996; 8: 57-66.
8. Endresen MJ, Tosti E, Heimli H, Lorentzen B, Henriksen T: Effects of free fatty acids found increased in women who develop preeclampsia on the ability of endothelial cells to produce prostacyclin, cGMP and inhibit platelet aggregation. Scand J Clin Lab Invest 1994; 54: 549-557.
9. Sattar N, Gaw A, Packard CJ, Greer IA: Potential pathogenetic roles of aberrant lipoprotein and fatty acid metabolism in preeclampsia. Br J Obstet Gynaecol 1996; 103: 614-620.
10. Redman CWG: Immunology of preeclampsia. Semin Perinatol 1991; 15: 257-262.
11. Stark JM: Preeclampsia and cytokine-induced oxidative stress. Br J Obstet Gynaecol 1993; 100: 105-109.
12. Meekins JW, McLaughlin PJ, West DC, Mac- Fadyen IR, Johnson PM: Endothelial cell activation by tumor necrosis factor-alpha (TNF-alpha) and the development of preeclampsia. Clin Exp Immunol 1994; 98: 110-114.
13. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK: Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200.
14. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB: The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994; 171: 944-948.
15. Lopez-Jaramillo P, Narvaez M, Calle A, Rivera J, Jacome P, Ruano C, Nava E: Cyclic guanosine 3́,5́ monophosphate concentrations in preeclampsia: effects of hydralazine. Br J Obstet Gynaecol1996; 103: 33-38.
16. Williams DJ, Vallance PJT, Neild H, Spencer JAD, Imms FJ: Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272:H748-H752.
17. Lopez-Jaramillo P: Calcium, nitric oxide, and preeclampsia. Semin Perinatol 2000; 24: 33-36.
18. Beinder E, Frobenius W: Die Präeklampsie: eine Endothelerkrankung? Dtsch Ärztebl 2000; 97:A2703-A2706.
19. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, Price K, Karumanchi SA, Valdés G: Endothelial dysfunction. A link among preeclampsia recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007; 49: 90-95.
20. Wang Y, Gu Y, Zhang Y, Lewis D: Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol 2004; 190: 817-824
21. Schiessl B, Mylonas I, Hantschmann P, Kuhn C, Schulze S, Kunze S, Friese K, Jeschke U: Expression of endothelial NO synthase, inducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. J Histochem Cytochem 2005; 53: 1441-1449.
22. Casanello P, Sobrevia L: Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT- 2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res 2002; 91: 127-134.
23. McCord N, Ayuk P, McMahon M, Boyd RCA, Sargent I, Redman C: Systems y+ arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia. Hypertension 2006; 47: 109-115.
24. Ayuk PTY, Theophanous D, D'Souza W, Sibley CP, Glazier JD: L -Arginine transport by the microvillous plasma membrane of the syncytiotrophoblast from human placenta in relation to nitric oxide production: effects of gestation, preeclampsia, and intrauterine growth restriction. J Clin Endocrinol Metab 2002; 87: 747-751.
25. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE: The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 1998; 4: 25-42. (Pubitemid 28223053)
26. Kobayashi T, Tokunaga N, Isoda H, Kanayama N, Terao T: Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome: proposal of an angiospastic syndrome of pregnancy. Semin Thromb Hemost 2001; 27: 131-135.
27. Förstermann U, Mügge A, Alheid U, Bode SM, Frölich JC: Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries. Eur Heart J 1989; 10(suppl F):36-43.
28. Hori T, Matsubara T, Ishibashi T, Ozaki K, Tsuchida K, Mezaki T, Tanaka T, Nasuno A, Kubota K, Nakamura Y, Yamazoe M, Aizawa Y, Nishio M: Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ J 2003; 67: 305-311.
29. Nakayama M, Yoshimura M, Sakamoto T, Shimasaki Y, Nakamura S, Ito T, Abe K, Yamamuro M, Miyamoto Y, Saito Y, Nakao K, Yasue H, Ogawa H: Synergistic interaction of T-786- 1 C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 2003; 13: 683-688.
30. Lowe DT: Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000; 4: 441-458.
31. Khan F, Belch JJ, MacLeod M, Mires G: Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46: 1123-1128. (Pubitemid 41533014)
32. Myers J, Mires G, Macleod M, Baker P: In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertens 2005; 45: 258-263. (Pubitemid 40179969)
33. Förstermann U, Closs EI, Pollock JS, et al: Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131.
34. Furchgott RF: The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 1984; 24: 175-197.
35. Böger RH, Bode-Böger SM, Frölich JC: The L -arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11.
36. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
37. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM: LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
38. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL: Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-887.
39. Tsikas D, Sandmann J, Böger RH, Gutzki FM, Mayer B, Frölich JC: Assessment of nitric oxide synthase activity by gas chromatography- mass spectrometry. J Chromatogr B 2000; 742: 143-153.
40. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
41. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
42. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97:e53-e59.
43. Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP: Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
44. Calver A, Collier J, Leone A, Moncada S, Vallance P: Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-194.
45. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177. (Pubitemid 38114135)
46. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolised by dimethylargi - nine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.
47. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
48. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
49. Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Hamsten A, Tornvall P: Mild-tomoderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-116.
50. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, Kruszelnicka- Kwiatkowska O, Kokot F, Dubiel J, Frölich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.
51. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE: Plasma levels of asymmetrical dimethyl- L -arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489-492.
52. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600.
53. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T: Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-2430.
54. Abbasi F, Asagami T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.
55. Yoo JH, Lee SC: Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-430.
56. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frölich JC: Elevated plasma and urine levels of ADMA and 15(S)-8-iso- PGF2alpha in end-stage liver disease. Hepatology 2003; 38: 1063-1064.
57. Roberts JM, Redman CW: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447-1451.
58. Hayman R, Warren A, Johnson I, Baker P: The preliminary characterization of a vasoactive circulating factor(s) in preeclampsia. Am J Obstet Gynecol 2001; 184: 1196-1203.
59. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GSJ: Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993; 342: 242-243.
60. Holden DP, Fickling SA, Whitley GSJ, Nussey SS: Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998; 178: 551-556.
61. Pettersson A, Hedner T, Milsom I: Increased circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998; 77: 808-813.
62. Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, Wennergren M, Hagberg H: Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand 2001; 80: 602-608.
63. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH: Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361: 1511-1517.
64. Prefumo F, Thilaganathan B, Whitley GS: First-trimester uterine artery resistance and maternal serum concentration of asymmetric dimethylarginine. Ultrasound Obstet Gynecol 2008; 31: 153-157.
65. Maas R, Serrano N, Schwedhelm E, Diaz LA, Casas JP, Böger RH, Lopez-Jaramillo P: Plasma concentration of asymmetrical dimethylarginine (ADMA) in women with pre-eclampsia from a high-risk population. J Am Med Assoc 2004; 291: 823-824.
66. Lopez-Jaramillo P, Casas JP, Serrano N: Preeclampsia: from epidemiological observations to molecular mechanisms. Braz J Med Biol Res 2001; 34: 1227-1235.
67. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, Wolzt M, Kautzky- Willer A: Circulating concentrations of asymmetrical dimethyl- L -arginine are increased in women with previous gestational diabetes. Diabetes 2002; 45: 1372-1378.
68. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426.
69. Félétou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder. Am J Physiol Heart Circ Physiol 2006; 291:H985-H1002.
70. Momohara Y, Sakamoto S, Obayashi S, Aso T, Goto M, Azuma H: Roles of endogenous nitric oxide synthase inhibitors and endothelin-1 for regulating myometrial contractions during gestation in the rat. Mol Hum Reprod 2004; 10: 505-512.
71. Noris M, Todeschimi M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porrati F, Benigni A, Picciolo C, Remuzzi G: L -Arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004; 43: 614-622.
72. Loyaga-Rendon RY, Sakamoto S, Beppu M, Aso T, Ishizaka M, Takahashi R, Azuma T: Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis 2005; 178: 231-239.
73. Siroen MPC, Teerlink T, Bolte AC, van Elburg RM, Richir MC, Nijveldt RJ, van der Hoven B, van Leeuwen PAM: No compensatory upregulation of placental dimethylarginine dimethylaminohydrolase activity in preeclampsia. Gynecol Obstet Invest 2006; 62: 7-13.
74. Bedford MT, Richard S: Arginine methylation an emerging regulator of protein function. Mol Cell 2005; 18: 263-272.
75. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540.
76. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214.
77. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095.
78. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575.
79. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, Welch WJ, Wilcox CS: Isoform-specific regulation by N(G),N(G)- dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007; 101: 627-635.
80. Akbar F, Heinonen S, Pirskanen M, Uimari P, Tuomainen TP, Salonen JT: Haplotypic association of DDAH1 with susceptibility to pre-eclampsia. Mol Hum Reprod 2004; 11: 73-77.
81. Schwedhelm E: Quantification of ADMA: analytical approaches. Vasc Med 2005; 10: S89-S95.
82. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH: Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51: 1268-1271.
83. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH: Highthroughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 211-219.
84. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH: Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383.
85. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH: Determination of a reference value for N(G), N(G)-dimethyl- L - arginine in 500 subjects. Eur J Clin Invest 2005; 35: 622-626.
86. Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC: Restoring vascular NO formation by L -arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-1344.
87. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH: Randomized, double-blind, placebo-controlled study of supplemental oral L -arginine in patients with heart failure. Circulation 1996; 93: 2135-2141.
88. Ceremuzynksi L, Chamiec T, Herbacynska- Cedro K: Effect of supplemental oral L -arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-333.
89. Böger RH, Ron ES: L -Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005; 10: 14-23.
90. Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A: L -Arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Invest 1999; 6: 202-207.
91. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henricksen T: Dietary supplementation with L -arginine or placebo in women with preeclampsia. Acta Obstet Gynecol Scand 2004; 83: 103-107.
92. Germain AM, Valdés G, Romanik MC, Reyes MS: Evidence supporting a beneficial role for long-term L -arginine supplementation in high-risk pregnancies. Hypertension 2004; 44:e1.
93. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP: L -Arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 2004; 43: 832-836.
94. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z: Effects of prolonged oral supplementation with L -arginine on pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005; 35: 32-37.
95. Neri I, Jasonni VM, Gori GF, Blasi I, Facchinetti F: Effect of L -arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J Matern Fetal Neonatal Med 2006; 19: 277-281.
96. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G: L -Arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.
97. Böger RH: Letter to the editor re: JAMA article on L-arginine therapy in acute myocardial infarction (letter). Altern Med Rev 2006; 11:91-92.
98. Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H: Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebocontrolled ARAMI pilot trial. Kardiol Pol 2005;62:421-427.
99. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP: L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116:188-195.